Circulating cell-free DNA (ccfDNA) has emerged as a promising diagnostic tool in oncology.
Identification of tumour-derived ccfDNA (ie circulating tumour DNA [ctDNA]) provides non …

Cancer cells shed naked DNA molecules into the circulation. This circulating tumor DNA
(ctDNA) has become the predominant analyte for liquid biopsies to understand the …

Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on
genomic alterations but have rarely considered the biological properties of plasma cell-free …

Circulating cell-free DNA (cfDNA) released by tumor cells, termed ctDNA, closely reflects the
heterogeneity of primary cancers and their metastases. As a noninvasive, real-time …

Qualitative and quantitative analysis of circulating cell-free DNA (cfDNA) is an emerging non-
invasive blood biomarker utilized to assess tumor progression and to evaluate prognosis …

In the current era of precision medicine, the identification of genomic alterations has
revolutionised the management of patients with solid tumours. Recent advances in the …

Tumors continually shed DNA into the circulation, where it can be noninvasively accessed.
The ability to accurately detect circulating tumor DNA (ctDNA) could significantly impact the …

Circulating tumor DNA (ctDNA) has garnered much excitement over the past few years for its
potential clinical utility as a surrogate for tumor biopsies in early cancer detection and …

Circulating tumor DNA (ctDNA) is tumor-derived, fragmented DNA that circulates freely in
body fluids, predominantly in the peripheral blood. Recently, ctDNA analysis has been …

Circulating tumor DNA (ctDNA) is a component of cell-free DNA (cfDNA) that is shed by
malignant tumors into the bloodstream and other bodily fluids. ctDNA can comprise up to …